MAST4

Across TCGA pan-cancer cohorts, MAST4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAST4 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAST4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAST4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where MAST4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.909	0.414	<.001	38	view →
HNSC	OS	Tertile	II,III,IV	0.812	0.562	.005	18	view →
LSCC	DFS	Median	All	0.609	0.808	.013	8	view →
PDAC	OS	Median	III,IV	0.373	0.796	.017	7	view →
LUAD	OS	Quartile	III,IV	1.000	0.851	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAST4–CCRCC (DFS)

Open the CCRCC breakdown →